Biopreservation refers to the process of preserving cells, tissues, organs, blood components, and genetic materials using advanced preservation media, cryogenic storage systems, and controlled freezing technologies. These solutions are designed to maintain the viability, stability, and functional integrity of biological materials during long-term storage, transportation, and downstream clinical or research use.
As personalized medicine, cell and gene therapies (CGTs), regenerative medicine, and genomic research expand globally, the need for reliable and scalable biopreservation infrastructure has become critical. From leukapheresis collections and engineered cell intermediates to viral vectors and final drug products, cryopreservation plays a central role in ensuring consistent therapeutic outcomes and regulatory compliance.
According to BIS Research, the global biopreservation market, valued at $4,316.3 million in 2024, is projected to reach $15,185.4 million by 2035, growing at a CAGR of 12.61% during the forecast period 2025-2035. This strong growth trajectory reflects the market’s foundational role in enabling next-generation healthcare and life sciences innovation.
Download the complete TOC and Request Sample Report
• Rapid expansion of cell and gene therapies and regenerative medicine programs
• Growth of global biobanks and gene banks supporting genomic and longitudinal studies
• Increasing volume of biological samples generated from biomedical research and clinical trials
• Rising commercialization of advanced therapies requiring GMP-compliant cryogenic storage
• Technological advancements in cryopreservation media, controlled-rate freezing, and robotics-enabled storage
• Growing demand for global cold-chain logistics and temperature-controlled supply chains
• High capital costs associated with ultra-low-temperature freezers and liquid nitrogen storage systems
• Significant operational expenses, including energy-intensive storage and LN2 refilling
• Risk of freezer failures, cryogenic supply disruptions, and sample loss
• Infrastructure limitations in low- and middle-income regions
• Regulatory complexity across global biobanking and advanced therapy networks
• November 2025: BioLife Solutions, Inc. inaugurated the Aby J. Mathew Center for Biopreservation Excellence at its expanded headquarters in Bothell, reinforcing innovation in cryopreservation science.
• October 2025: Cryoport, Inc. opened a 55,000-square-foot Global Supply Chain Center in Louvres, France, near Charles de Gaulle Airport to strengthen temperature-controlled logistics for advanced therapies.
• April 2025: BioLife Solutions, Inc. acquired PanTHERA CryoSolutions, Inc., integrating proprietary Ice Recrystallization Inhibitor (IRI) technology to enhance its consumables portfolio and scientific capabilities.
According to Research Analyst at BIS Research: “The biopreservation market is entering a high-growth phase, fueled by the accelerating pipeline of cell and gene therapies and the rapid expansion of global biobanking infrastructure. As precision medicine and regenerative therapies scale worldwide, demand for advanced cryopreservation media, automated storage platforms, and digitally integrated monitoring systems will continue to rise. Biopreservation is no longer a supporting function it is a critical infrastructure layer underpinning next-generation healthcare innovation.”
The biopreservation market is projected to grow from $4,316.3 million in 2024 to $15,185.4 million by 2035, registering a CAGR of 12.61% during 2025-2035.
Key players include BioLife Solutions, Inc., Thermo Fisher Scientific Inc., Sartorius AG, Azenta, Inc., Bio-Techne, Cryoport Systems, LLC, Danaher Corporation (Cytiva), PHC Corporation, Alpha Teknova, Inc., Eppendorf SE, ThermoGenesis, OriGen Biomedical, Inc., X-Therma, Inc., STEMCELL Technologies, and IC Biomedical, LLC.
Biopreservation media leads the market by product, while research applications and biobanks/genebanks dominate by application and end user, respectively.
BIS Research provides expert-driven insights, granular segmentation, and strategic advisory across healthcare, biotechnology, and advanced therapy markets.
